RESUMO

Patients with critical illness develop physiological dysfunction which provokes multi-organ system failure and triggers fatal outcomes and irreversible injuries or even death. Inside Internal Medicine services of Mexican hospitals, especially in public hospitals, there is a considerable number of critically ill patients with multiple pathologies who require surveillance to reach clinical goals of their treatment. We present a summary of guidelines and goals of the most prevalent critical diseases inside Internal Medicine services, which are necessary to guide treatments.

Los pacientes en estado crítico presentan disfunción fisiológica que provoca inestabilidad en órganos y sistemas del cuerpo, con desenlaces fatales y lesiones irreversibles o incluso la muerte. En los servicios de Medicina Interna de los hospitales de México, en especial en los públicos, hay pacientes críticos con múltiples patologías que requieren vigilancia en el cumplimiento de diversas metas de su tratamiento. Se presenta un compendio de las guías y metas de patologías críticas con mayor prevalencia en los servicios de Medicina Interna, las cuales son necesarias para guiar el tratamiento.

Assuntos

RESUMO

Los pacientes en estado crítico presentan disfunción fisiológica que provoca inestabilidad en órganos y sistemas del cuerpo, con desenlaces fatales y lesiones irreversibles o incluso la muerte. En los servicios de Medicina Interna de los hospitales de México, en especial en los públicos, hay pacientes críticos con múltiples patologías que requieren vigilancia en el cumplimiento de diversas metas de su tratamiento. Se presenta un compendio de las guías y metas de patologías críticas con mayor prevalencia en los servicios de Medicina Interna, las cuales son necesarias para guiar el tratamiento.

Patients with critical illness develop physiological dysfunction which provokes multi-organ system failure and triggers fatal outcomes and irreversible injuries or even death. Inside Internal Medicine services of Mexican hospitals, especially in public hospitals, there is a considerable number of critically ill patients with multiple pathologies who require surveillance to reach clinical goals of their treatment. We present a summary of guidelines and goals of the most prevalent critical diseases inside Internal Medicine services, which are necessary to guide treatments.

Assuntos

RESUMO

Introdução: Queda é o acidente que ocorre com maior frequência no idoso, sendo a principal causa de morte naqueles com mais de 65 anos. As fraturas do quadril ocupam um papel de grande importância, gerando grande problema de ordem clínica envolvendo pacientes e familiares e de ordem econômica para a sociedade. Objetivo: Coletar dados de questionário da admissão e correlacionar a presença de comorbidades prévias a mortalidade em 30 dias do pós-cirurgia. Métodos: Estudo retrospectivo observacional não randomizado com 216 pacientes com fraturas cirúrgicas do quadril com 61 anos ou mais de idade atendidos no setor de emergência do Centro Hospitalar São Lucas na cidade de Niterói, RJ, no período de 30/03/2016 a 20/03/2018. Resultados: A incidência de óbito após a cirurgia do quadril é igual a 6,9% no primeiro mês. O paciente com fratura no quadril tem comorbidades cardiovasculares (75,9%). O óbito está associado à comorbidade hepática em 13,3% e ao baixo peso em 33,3%. O fato de ter duas ou mais comorbidades não está significativamente associado ao óbito. Conclusão: As comorbidades hepáticas, o baixo peso e a presença de disfunções cardiovasculares são importantes preditores prognósticos na mortalidade do paciente com mais de 61 anos após cirurgia de fratura do fêmur no primeiro mês. (AU)

Introduction: Falls are the leading cause of accidents and death in those aged 65 and above. The high incidence of these injuries impact patients, their families and it represents an economic problem for society. Objective: Collect data from the admission survey and correlate previous comorbidities to mortality in 30 days after surgery. Methods: Retrospective observational non-randomized study. 216 patients were included, aged 61 years or older, who were admitted at the emergency department of the Centro Hospitalar São Lucas in Niterói city, Rio de Janeiro. All the participants were candidates of hip fracture surgery between 03/30/2016 and 03/20/2018. Results: The mortality after hip surgery was 6.9% in the first month. Patients who underwent hip surgery had, previously, cardiovascular diseases (75.9%). Death was associated with liver comorbidity in 13.3% and low weight in 33.3%. The fact of having two or more comorbidities was not associated with death. Conclusion: Liver and cardiovascular diseases and low weight are important prognostic predictors in mortality of patients over 61 years of age after femoral fracture surgery in the first month. (AU)

Assuntos

RESUMO

INTRODUCTION AND OBJECTIVES: The incidence of liver injury (LI) in hospitalized COVID-19 patients ranged from 14% to 53% based on sole or multiple elevated indexes for LI. The aims of our study were to investigate the changes of parameters (ALT, AST) in LI and determine the risk factors for LI in a cohort of 830 COVID-19 patients. METHODS: Demographic information, clinical features, and laboratory testing outcomes on admission were compared between patients with and without liver biochemistry abnormality (LBA). The same comparisons were performed between the LBA and LI groups. The updated RUCAM was used to determine the causality between drugs application and LI. Univariable and multivariable logistic regression analyses were used to explore the potential risk factors associated with LBA and LI. RESULTS: A total of 227 (27.3%) patients exhibited LBA and 32 (3.9%) patients were categorized as having LI based on the diagnostic criteria. 32.6% (74/227) of the LBA patients had RUCAM score >3, whereas the non-LBA patients had a slight lower at rate of 24.2% (146/603) (P?=?0.047). Multivariable regression showed that a higher incidence of LBA was associated with hepatic hypoattenuation on computed tomography (CT) (odds ratio: 2.243, 95% confidence interval: 1.410-3.592, p?=?0.001), lymphocyte proportion <20% (2.088, 1.476-2.954, p?1?mg/dL (2.650, 1.845-3.806, p?1 (2.558, 1.820-3.596, p?1.0?mg/dL, lymphocyte proportion <20%, AST/ALT ratio <1, and triglyceride levels >1.7?mol/L are potential risk factors for LI.

Assuntos

RESUMO

Resumen ANTECEDENTES La administración de vitamina K se restringe a situaciones, como antídoto de los antagonistas de vitamina K y enfermedad hemorrágica del recién nacido, pero debido a su papel en la hemostasia, su administración se ha extendido al tratamiento de otras enfermedades, como la enfermedad hepática crónica. OBJETIVO Identificar la eficacia de adicionar vitamina K al tratamiento de los pacientes con insuficiencia hepática terminal con algún estado de descompensación. MATERIAL Y MÉTODO Estudio de casos y controles retrospectivo realizado en el periodo 2016-2017 en pacientes con enfermedad hepática crónica estadio Child-Pugh C durante un episodio de descompensación. La vitamina K (bisulfito sódico de menadiona) se administró a dosis de 10 mg vía intramuscular cada 12 h durante tres días. RESULTADOS Se estudiaron 60 pacientes, 30 recibieron vitamina K, en caso de un evento hemorrágico se administró en conjunto terapia de sustitución con plasma fresco congelado y crioprecipitados. La media de edad fue de 60 (25-86) años, todos los casos eran del género masculino. La principal causa de complicación fue la hemorragia (85%). Cinco casos (8.3%) fallecieron por reactivación de la hemorragia. Administrar vitamina K no acortó las pruebas de coagulación (TP, TTPa, INR) ni mostró beneficio en la mortalidad. Sólo la trombosis como la encefalopatía mostró asociación con la mortalidad. CONCLUSIÓN La adición de vitamina K no influye en las complicaciones en pacientes con enfermedad hepática terminal.

Abstract BACKGROUND The administration of vitamin K are restricted to situations such as an antidote for vitamin K antagonists and hemorrhagic disease of the newborn, but due to its role in hemostasis, its use has been extended to other diseases, such as terminal chronic liver disease. OBJECTIVE To identify the efficacy of adding vitamin K to the management of patients with terminal hepatic insufficiency with some state of decompensation. MATERIAL AND METHOD A retrospective case-control study was done between 2016-2017 in patients with Child-Pugh C chronic liver disease during an episode of decompensation. Vitamin K (menadione sodium bisulfite) was administered at a dose of 10 mg intramuscular every 12 h for three days. RESULTS A total of 60 patients were studied, 30 received vitamin K, in the case of a hemorrhagic event, replacement therapy with fresh frozen plasma and cryoprecipitates were administered together. The mean age was 60 (25-86) years; all were male. Hemorrhage (85%) was the main cause of complication. Five cases (8.3%) died due to reactivation of the hemorrhage. The administration of vitamin K did not shorten the coagulation tests (TP, aPTT, INR) nor showed a mortality benefit. Only thrombosis such as encephalopathy showed an association on mortality. CONCLUSION The addition of vitamin K does not influence the complications in patients with terminal liver disease.

RESUMO

RESUMO Objetivo: avaliar a dimensão psicossocial da qualidade de vida de pacientes antes e depois do transplante hepático. Método: estudo descritivo, transversal, com abordagem quantitativa, com 150 pacientes submetidos ao transplante de fígado em seguimento a partir do sexto mês, no ambulatório de um centro de referência em transplante hepático. A coleta de dados foi realizada a partir da aplicação de um instrumento com dados sociodemográficos/clínicos e do questionário Liver Disease Quality of Life. Foi utilizada análise estatística descritiva, teste t de Student para comparação das médias dos domínios e Games-Howell para comparações múltiplas. Resultados: houve melhoria nos níveis de qualidade de vida pós-transplante nos quatro domínios avaliados (<0,0001), com maior elevação de escores para os domínios: preocupação (55,5 vs 87,9) e estigma da doença hepática (58,6 vs 93,7). Conclusão: o estudo demonstrou que os pacientes submetidos ao transplante hepático obtiveram uma melhoria significativa da percepção da qualidade de vida no que diz respeito à dimensão psicossocial, sendo mais perceptiva nos domínios preocupação e estigma da doença hepática.

RESUMEN Objetivo: evaluar la dimensión psicosocial de la calidad de vida de los pacientes antes y después del trasplante hepático. Método: estudio descriptivo, transversal y con un abordaje cuantitativo con 150 pacientes sometidos al trasplante de hígado y en seguimiento a partir del sexto mes, en el ambulatorio de un centro de referencia en trasplante hepático. La obtención de datos se realizó a partir de la aplicación de un instrumento con datos sociodemográficos/clínicos y del cuestionario Liver Disease Quality of Life. Se utilizó el análisis estadístico descriptivo, la prueba t de Student para la comparación de los promedios de los dominios y Games-Howell para las comparaciones múltiples. Resultados: hubo mejoras en los niveles de calidad de vida post-trasplante en los cuatro dominios evaluados (<0,0001), con una elevación mayor de resultados para los dominios preocupación (55,5 vs 87,9) y estigma de la enfermedad hepática (58,6 vs 93,7). Conclusión: el estudio demostró que los pacientes sometidos al trasplante hepático consiguieron una significativa mejora de la percepción de la calidad de vida en relación a la dimensión psicosocial, siendo más perceptivo en los dominios de preocupación y estigma de la enfermedad hepática.

ABSTRACT Objective: to assess the psychosocial dimension of patients' quality of life before and after a hepatic transplantation. Method: descriptive, cross-sectional study of quantitative approach, with 150 patients submitted to a liver transplantation being monitored from the sixth month, in the outpatient clinic of a reference center in hepatic transplantation. The data collection was carried out through an instrument with sociodemographic/clinical data and the Liver Disease Quality of Life questionnaire. The descriptive statistical analysis, Student's t-test for comparison of domain means, and Games-Howell for multiple comparisons have been used. Results: there was improvement in the post-transplant quality of life in the four domains evaluated (<0.0001),with higher scores for the domains: health distress (55.5 vs 87.9) and stigma of hepatic disease (58.6 vs 93.7). Conclusion: the study has demonstrated that patients submitted to a liver transplantation had a significant improvement in the perception of quality of life regarding the psychosocial dimension, being more perceptive in the areas of health distress and stigma of hepatic disease.

Assuntos

RESUMO

OBJECTIVES: Patients receiving treatment for tuberculosis are at risk of developing acute liver failure due to the hepatotoxicity of antitubercular drugs. We aimed to describe our experience with liver transplantation from deceased donors in this situation. METHODS: We identified patients undergoing transplantation for acute liver failure due to antitubercular drugs in our prospectively maintained database. RESULTS: Of 81 patients undergoing transplantation for acute liver failure, 8 cases were attributed to antitubercular drugs during the period of 2006-2016. Regarding the time of tuberculosis treatment until the onset of jaundice, patients were on antitubercular drugs for a mean of 64.7 days (21-155 days). The model for end-stage liver disease (MELD) score of patients ranged from 32 to 47 (median 38), and seven patients underwent transplantation under vasopressors. The 1-year survival was 50%. Three patients died during the week following transplantation due to septic shock (including a patient with acute liver failure due to hepatic/disseminated tuberculosis), and the remaining patient died 2 months after transplantation due to pulmonary infection. There were 2 cases of mild rejection and 1 case of moderate rejection. Of the surviving patients, all were considered cured of tuberculosis after alternative drugs were given. CONCLUSION: Patients arrived very sick and displayed poor survival after deceased donor transplantation.

Assuntos

RESUMO

PURPOSE: To evaluate the efficacy of portal vein embolization (PVE) with n-Butyl-cyanoacrylate (NBCA) through an ipsilateral approach before major hepatectomy. Secondary end-points were PVE safety, liver resection and patient outcome. METHODS: Over a 5-year period 50 non-cirrhotic consecutive patients were included with primary or secondary liver cancer treatable by hepatectomy with a liver remnant (FLR) volume less than 25% or less than 40% in diseased livers. RESULTS: There were 37 men and 13 women with a mean age of 57 years. Colorectal liver metastases were the most frequent tumor and patients were previously exposed to chemotherapy. FLR increased from 422 ml to 629 ml (P < 0.001) after PVE, corresponding to anincrease of 52%. The FLR ratio increased from 29.6% to 42.3% (P < 0.001). Kinetic growth rate was 2.98%/week. A negative association was observed between increase in the FLR and FLR ratio and FLR volume before PVE (P = 0.002). In 31 patients hepatectomy was accomplished and only one patient presented with liver insufficiency within 30 days after surgery. CONCLUSIONS: PVE with NBCA through an ipsilateral puncture is effective before major hepatectomy. Meticulous attention is needed especially near the end of the embolization procedure to avoid complications. TRIAL REGISTRATION: Clinical Study ISRCTN registration number: ISRCTN39855523 . Registered March 13th 2017.

Assuntos

RESUMO

ABSTRACT Intracranial hypertension and brain swelling are a major cause of morbidity and mortality of patients suffering from fulminant hepatic failure (FHF). The pathogenesis of these complications has been investigated in man, in experimental models and in isolated cell systems. Currently, the mechanism underlying cerebral edema and intracranial hypertension in the presence of FHF is multi-factorial in etiology and only partially understood. The aim of this paper is to review the pathophysiology of cerebral hemodynamic and metabolism changes in FHF in order to improve understanding of intracranial dynamics complication in FHF.

RESUMO O edema cerebral e a hipertensão intracraniana (HIC) são as principais causas de morbidade e mortalidade de pacientes com insuficiência hepática fulminante (IHF). A patogênese dessas complicações tem sido investigada no homem, em modelos experimentais e em sistemas celulares isolados. Atualmente, o mecanismo subjacente ao edema cerebral e HIC na presença de IHF é multifatorial em etiologia e pouco compreendido na literatura. O objetivo deste trabalho é revisar a fisiopatologia das alterações hemodinâmicas e metabólicas cerebrais na IHF, visando melhorar a compreensão da complicação da hemodinâmica encefálica na IHF.

Assuntos

RESUMO

Introducción: La Tuberculosis Espinal corresponde a una infección causada por Mycobacteriun tuberculosis localizada en la región vertebral. El tratamiento farmacológico de esta patología no está exento de complicaciones, principalmente dado por la toxicidad hepática. El caso clínico a presentar se centra en el tratamiento farmacológico en un paciente con Insuficiencia Hepática. Presentación del caso: Paciente de 58 años con antecedentes de Insuficiencia Hepática, inició cuadro de 3 meses de evolución caracterizado por dolor lumbar progresivo con escasa a nula respuesta a tratamiento analgésico. Al examen físico destacó dolor axial de columna lumbar, paresia M4 en L5, Lasegue y Tepe (-). Se solicitaron exámenes de imagenología y laboratorio, confirmándose probable diagnóstico de Tuberculosis Espinal. Se inició tratamiento antituberculoso alternativo. Discusión: El tratamiento universalmente aceptado es la asociación de Isoniazida, Rifampicina, Pirazinamida, Etambutol. En relación al caso clínico y a la Insuficiencia Hepática se recomienda no utilizar Pirazinamida y ante riesgo alto reemplazar el uso de Isoniazida por Fluoroquinolona. Además se recomienda medir enzimas hepáticas al inicio del tratamiento y durante su mantención. En caso de encontrarse elevadas, se recomienda iniciar un esquema con mínimo riesgo de toxicidad hepática, asociando Estreptomicina - Etambutol, mientras se normalizan las alteraciones. En el caso clínico presentado el esquema antibiótico considera la asociación de Estreptomicina, Etambutol y Fluoroquinolona. Es importante reconocer la clínica de la Tuberculosis Espinal, con el fin de proporcionar un tratamiento oportuno y eficaz, considerando el riesgo de hepatoxicidad de éste y su indicación en pacientes con diagnóstico de Insuficiencia Hepática.

Introduction: Spinal Tuberculosis corresponds to an infection caused by Mycobacterium tuberculosis located in the vertebral region. The pharmacological treatment of this pathology is not free of complications, mainly due to liver toxicity. The clinical case to be presented focuses on the pharmacological treatment in a patient with Hepatic Insufficiency. Case report: A 58-year-old patient with a history of Hepatic Insufficiency, started a 3-month evolution characterized by progressive lumbar pain with little to no response to analgesic treatment. Physical examination revealed lumbar spine axial pain, M4 paresis in L5, Lasegue and Tepe (-). Imaging and laboratory tests were requested, confirming the probable diagnosis of Spinal Tuberculosis. Alternative antituberculous treatment was started. Discussion: The universally accepted treatment is the association of Isoniazide, Rifampin, Pyrazinamide, Ethambutol. In relation to the clinical case and Hepatic Insufficiency, it is recommended not to use Pyrazinamide and at high risk to replace the use of Isoniazide with Fluoroquinolone. It is also recommended to measure liver enzymes at the start of treatment and during maintenance. In case of being elevated, it is recommended initiate a scheme with minimal risk of liver toxicity, associating Streptomycin - Ethambutol, while the alterations are normalized. In the clinical case presented, the antibiotic scheme considers the association of Streptomycin, Etambutol and Fluoroquinolone. It is important to recognize the clinic of Spinal Tuberculosis, in order to provide timely and effective treatment, considering the risk of hepatoxicity thereof and its indication in patients diagnosed with Hepatic Insufficiency

Assuntos

RESUMO

Hepatorenal syndrome (HRS) is defined as a failure of renal function, potentially reversible, in patients with liver cirrhosis and ascites. Recently, a component of cardiomyopathy associated with HRS was described, but the use of positive inotropic medicine as part of the treatment of the acute phase has not been extensively evaluated. We report a second case in our hospital of a patient with HRS type I without previous heart disease, with secondary hemodynamic decompensation due to liver disease, in which the abnormalities in systolic function by speckle-tracking echocardiography were observed and could be reversed by the use of inotropes. After partial response to current therapies, the patient presented a clinical and laboratorial response with improvement of renal function after infusion of dobutamine. Clinical studies are needed for the therapy approach to HRS taking into account myocardial dysfunction as a major contributing factor for renal dysfunction.

RESUMO

Introduction: Hepatopulmonary syndrome (HPS) is a serious, progressive disease. Its pathophysiology resides in a hypoxic intrapulmonary shunt and severe clinical deterioration. Liver transplantation (LT) is the only effective treatment in appropriately selected patients. Objective: To acknowledge the importance of early diagnosis of HPS. Patients and methods: Observational, descriptive, retrospective trial including 8 patients with HPS that received LT between April 2006 and August 2014. The clinical data prior to transplantation and follow-up after the procedure were reviewed. A multivariate analysis (stepwise forward logistic regression analysis) was used to identify the variable that could potentially increase the risk of death. Results: Of the 8 patients, death could only be significantly predicted based on the pre-LT arterial blood partial oxygen pressure (PaO2) (p = 0.002). The average pre-LT PaO2 of the patients that died was 51.5 ±2.49 SD, with a statistically significant difference (p = 0.002). None of the variables was statistically significant for HPS reversibility. The survival rate of patients diagnosed with HPS following the LT was 62.5%. Conclusions: The level of pre-LT hypoxemia is an important predictor for immediate postoperative mortality. Early detection of the condition is critical to reduce the post LT morbidity and mortality so that the indication for transplant is made at the right time, regardless of the stage of liver disease. The most efficient clinical strategy could be the use of appropriate early detection protocols for HPS through screening of hypoxemia in patients with portal hypertension.

Introducción: El síndrome hepatopulmonar (SHP) es una enfermedad grave y progresiva cuya fisiopatología reside en un shunt intrapulmonar con hipoxia y deterioro clínico severo. Como único tratamiento efectivo se ha postulado el trasplante hepático (TH), en pacientes adecuadamente seleccionados. Objetivo: Reconocer la importancia del diagnostico temprano del SHP. Pacientes y métodos: Mediante un estudio observacional, descriptivo, con carácter retrospectivo de 8 pacientes con SHP, a los que se les realizó TH en el período entre Abril 2006-Agosto 2014. Se han revisado los datos clínicos previos al trasplante y el seguimiento tras este. Se empleó un estudio multivariante (stepwise forward logistic regression analisis), para determinar cual variable podría incrementar el riesgo de muerte. Resultados: De los 8 pacientes, el resultado de muerte sólo pudo ser predicho significativamente por el factor presión parcial de oxígeno en sangre arterial (PaO2) pre-TH (p=0,002). La PaO2 pre-TH promedio de los pacientes que fallecieron era de 51,5 +/- 2,49 DS, siendo la diferencia estadísticamente significativa (p=0,002). Ninguna variable resultó estadísticamente significativa para reversibilidad del SHP. La supervivencia de los pacientes con criterio de SHP posterior al TH fue de 62,5%. Conclusiones: El grado de hipoxemia pre-TH es un factor predictor importante de mortalidad en el postoperatorio inmediato. La precocidad en la detección de la entidad es fundamental tanto para disminuir la morbimortalidad post TH como para indicar éste en el momento óptimo independientemente del estadío de la enfermedad hepática. Protocolos adecuados de detección precoz del SHP mediante screening de hipoxemias en pacientes con hipertensión portal, puede ser la estrategia clínica más eficiente.

Assuntos

RESUMO

A cardiomiopatia cirrótica (CMC) é uma disfunção cardíaca crônica que acomete pacientes cirróticos sem doença cardíaca prévia. Trata-se de uma doença inicialmente assintomática que se manifesta em situações de maior demanda metabólica, devido a menor capacidade cardíaca em aumentar seu inotropismo. O diagnóstico é pautado em alterações eletrocardiográficas e ecocardiográficas. Ainda não há tratamento específico para a CMC, sendo instituídas medicações sintomáticas semelhantes ao tratamento da insuficiência cardíaca. Esta revisão tem por objetivo descrever os aspectos fisiopatológicos, clínicos e diagnósticos da CMC, evidenciando as características clínicas, laboratoriais e eletro e ecocardiográficas no rastreio da disfunção cardíaca nos pacientes cirróticos.

Cirrhotic cardiomyopathy (CCM) is a chronic cardiac dysfunction that affects cirrhotic patients without history of heart disease. It is an initially asymptomatic disease that appears in situations of increased metabolic demand due to lower cardiac capacity to increase inotropism. Diagnosis is based on disorders revealed by electrocardiography and echocardiography. There is no specific treatmentfor CCM. Similar symptomatic medications are established to treat heart failure. This review aims to describe the pathophysiological, clinical and diagnostic aspects of CCM, showing the clinical, laboratory, electrocardiographic and echocardiographic characteristics in assessing cardiac dysfunction in cirrhotic patients.

Assuntos

RESUMO

INTRODUCTION: Not responsible self-medication refers to drug use in high doses without rational indication and often associated with alcohol abuse. It can lead to liver damage and drug interactions, and may cause liver failure. AIM: To warn about how the practice of self-medication can be responsible for acute liver failure. METHOD: Were used the Medline via PubMed, Cochrane Library, SciELO and Lilacs, and additional information on institutional sites of interest crossing the headings acute liver failure [tiab] AND acetaminophen [tiab]; self-medication [tiab] AND acetaminophen [tiab]; acute liver failure [tiab] AND dietary supplements [tiab]; self-medication [tiab] AND liver failure [tiab] and self-medication [tiab] AND green tea [tiab]. In Lilacs and SciELO used the descriptor self medication in Portuguese and Spanish. From total surveyed were selected 27 articles and five sites specifically related to the purpose of this review. CONCLUSIONS: Legislation and supervision disabled and information inaccessible to people, favors the emergence of cases of liver failure drug in many countries. In the list of released drugs that deserve more attention and care, are some herbal medicines used for the purpose of weight loss, and acetaminophen. It is recommended that institutes of health intensify supervision and better orient their populations on drug seemingly harmless, limiting the sale of products or requiring a prescription for release them. .

INTRODUÇÃO: Automedicação não responsável refere-se ao uso de medicamentos em altas doses, sem parâmetros racionais e associada frequentemente ao álcool. Ela pode levar à interações medicamentosas danosas ao fígado, podendo causar falência hepática. OBJETIVO: Alertar sobre o quanto a prática da automedicação não responsável pode levar falência hepática aguda. MÉTODO: Foram utilizadas as bases Medline via PubMed, Cochrane Library, SciELO e Lilacs, e informações adicionais em sites institucionais de interesse cruzando os descritores acute liver failure[tiab] AND acetaminophen[tiab]; self-medication[tiab] AND acetaminophen[tiab]; acute liver failure[tiab] AND dietary supplements[tiab]; self-medication[tiab] AND liver failure[tiab]; e self-medication[tiab] AND green tea[tiab]. Na Lilacs e SciELO utilizou-se o descritor automedicação em português e espanhol. Do total pesquisado selecionou-se 27 artigos e cinco sites relacionados especificamente ao objetivo desta revisão. CONCLUSÕES: Legislação e fiscalização deficientes e informações pouco acessíveis à população favorecem ao aparecimento de casos de falência hepática medicamentosa em diversos países. Na lista de medicamentos liberados que merecem maior atenção e cuidado, encontraram-se alguns fitoterápicos utilizados com o objetivo de emagrecer, e o analgésico paracetamol. Recomenda-se que organismos nacionais de farmacovigilância intensifiquem a fiscalização e melhor orientem suas populações no consumo de medicamentos aparentemente inofensivos, limitando a sua venda produtos ou exigindo receita médica para liberação. .

Assuntos

Assuntos

RESUMO

O transplante hepático inter vivos adulto expandiu as possibilidades terapêuticas para pacientes com insuficiência hepática terminal. A necessidade de um volume hepático adequado que será retirado do doador e necessário ao receptor limita sua utilização em alguns casos. Apresentamos um caso em que se utilizou dois lobos esquerdos de dois doadores vivos no intuito de prover parênquima hepático suficiente ao receptor.

Living donor liver transplantation expanded the therapeutic possibilities for liver failure patients. The necessary correct match between the liver mass donated and received sometimes limits its use. A case that was used two left liver grafts from adult living donors is reported.

Assuntos

RESUMO

Introducción. Los sistemas de soporte hepático extracorpóreo (SHE) surgen como una alternativa al trasplante hepático (TH), dado el incremento en la incidencia de falla hepática aguda (FHA), falla hepática crónica agudizada (FHCA), así como las restricciones en la oferta de órganos. Objetivo. Revisión de la literatura de los sistemas de soporte hepático extracorporeo. Metodología. Búsqueda de la literatura publicada entre julio de 1990 y noviembre de 2010 en las principales bases de datos médicas que incluyeron MEDLINE, SciELO y EMBASE, de artículos que analizaran tecnologías relacionadas con sistemas de soporte hepático en cuanto a sus especificaciones técnicas, sus usos y la evidencia respecto a su efectividad en pacientes con algún tipo de falla hepática que requirieran soporte.Resultados. Estos sistemas pueden dividirse en artificiales (hemofiltración, sistema MARS) y bioartificiales (como el Hepatassist™). Su fundamento consiste en reemplazar los procesos de destoxificación relacionados específicamente con el sistema de bilirrubinas, la eliminación de aminoácidos aromáticos, agentes inflamatorios y el manejo de los productos de degradación del sistema de la coagulación. Los recientes avances en bioingeniería y biogenética han hecho que estas tecnologías se acerquen cada vez más a una forma ideal, permitiendo que sean utilizados con relativo éxito en humanos. Los SHE, en su gran mayoría en desarrollo, pretenden no solo actuar como puente al TH, sino que, en casos puntuales, pueden llegar a ser la piedra angular del tratamiento mientras la FHA logra resolverse.

Background. Extracorporeal liver support systems (ELS) have emerged as an alternative to liver transplant (LT), given the growing incidence of acute liver failure (ALF), acute-on-chronic liver failure (ACLF) and the limited organ supply. Objective. Review of literature about Extracorporeal Liver Support Systems. Methodology. A literature search was conducted on the main medical databases including MEDLINE, SciELO and EMBASE for papers published between July 1990 and November 2010 looking at technologies associated with liver support systems, their technical specifications, their use, and evidence regarding their effectiveness in patients with some forms of liver failure requiring support. Results. These systems may be divided into artificial (hemofiltration, MARS) and bioartificial (such as the Hepatassist™). They work by replacing detoxification processes associated specifically with bilirubins, aromatic aminoacids, and inflammatory agents, and the elimination of breakdown products of coagulation. Recent advances in bioengineering and biogenetics have brought these technologies closer to hetheideal, enabling their use in humans with a relative degree of success. ELS systems, most of them still under development, are designed not only to act as a bridge for LT but may also become the cornerstone of treatment in specific cases while the ALF resolves.

Assuntos

RESUMO

Schistosomiasis is one of the most common parasitic diseases, still considered of public health significance. Acute schistosomiasis is of difficult diagnosis and therefore has been overlooked, misdiagnosed, underestimated and underreported in endemic areas. The delay between the exposure to contaminated water and the initial symptoms may explain this challenging diagnosis. Acute schistosomiasis is frequently reported in non-immune individuals while reinfection cases occurring in endemic areas is scarcely documented. The later usually shows a benign course but fatal cases do exist. The authors report a case of a young female patient, in the late puerperium, with a three-month history of weight loss, intermittent fever, cough, thoracic and abdominal pain and increased abdominal girth. Physical examination showed a tachycardia, tachypnea and hypotension. Laboratory tests showed a mild anemia, eosinophilia, and a slightly elevation of liver enzymes. Thorax and abdominal multidetector computed tomography evidenced a diffuse and bilateral pulmonary micronodules and peritoneal and intestinal wall thickening. The patient progressed rapidly to hepatic insufficiency, and death after respiratory insufficiency. An autopsy was performed and the findings were compatible with acute Schistosomiasis in a patient previously exposed to Schistosoma mansoni.

RESUMO

RACIONAL: A função hepática é um processo complexo que envolve múltiplos eventos celulares. Ela, em pacientes cirróticos, pode se beneficiar da terapia com oxigênio hiperbárico. OBJETIVO: Avaliar, de forma preliminar, os dados clínicos e laboratoriais sobre a função hepática em pacientes cirróticos em lista de espera para transplante hepático, submetidos à oxigenoterapia hiperbárica. MÉTODO: Estudo prospectivo com intervenção, no qual 10 pacientes foram escolhidos aleatoriamente entre os pacientes cirróticos em lista de espera para transplante hepático. A idade variou de 20 a 65 anos, e todos apresentaram escore MELD maior que 15. Todos os pacientes foram submetidos a nove sessões de terapia com oxigênio hiperbárico, em dias alternados com a duração de 60 minutos por sessão, com atmosfera de oxigênio de 100 por cento e pressão de 2,8 ATM. As variáveis dependentes foram os valores laboratoriais bioquímicos e hematológicos, avaliados antes e após sessões de terapia hiperbárica de oxigênio, além de parâmetros clínicos, considerando-se também o Child-Turcotte-Pugh e o MELD. A análise estatística foi realizada com o SPSS (Statistcal Package for Social Sciences), e incluiu média com desvio-padrão. RESULTADOS: Trêspacientes (30 por cento) relataram diminuição no número e intensidade da encefalopatia. Não houve casos de peritonite bacteriana espontânea e sangramento gastrointestinal, e não houve aumento na gravidade da ascite. Dois pacientes relataram melhora no prurido, e quatro melhora no estado geral em poucas semanas após sessões de oxigenoterapia hiperbárica. CONCLUSÃO: A oxigenoterapia hiperbárica pode melhorar a função hepática na cirrose e ajudar a controlar as complicações relacionadas à insuficiência hepática na avaliação pré-operatória para transplante de fígado.

BACKGROUND: Hepatic function is a complex process which involves multiple celular events. Liver function in cirrhotic patients may be benefited with hyperbaric oxygen therapy. AIM: To evaluate clinical and laboratorial data regarding liver function in cirrhotic patients selected for liver transplantation, submitted to hyperbaric oxygen therapy. METHOD: A prospective interventional study was designed, wherein 10 patients were randomized amongst cirrhotic patients selected for liver transplantation. The ages ranged from 20 to 65 years, and all patients presented with a MELD score greater than 15. All patients were submitted to nine sessions of hyperbaric oxygen therapy, on alternated days with the duration of 60 minutes per session, with oxygen atmosphere of 100 percent and a 2,8 ATM pressure. Dependent parameters included were biochemical and hematologic laboratory values, evaluated before and after hyperbaric oxygen therapy sessions, besides clinical parameters, evaluated considering the Child-Turcotte-Pugh and the MELD scores. Statistical analysis was performed with SPSS (Statistcal Package for Social Sciences). RESULTS: Three patients (30 percent) reported decrease in the number and intensity of encephalopathy. There were no cases of spontaneous bacterial peritonitis and gastrointestinal bleeding, and there were no increases on the severity of ascitis. Two patients reported improvement on pruritus, and four improvement on the general status for few weeks following hyperbaric oxygen sessions. CONCLUSION: Hyperbaric oxygen therapy may improve liver function in cirrhosis, and may help to control complications related to liver failure on the preoperative evaluation for liver transplantation.

RESUMO

OBJETIVO: Descrever as formas de apresentação, as alterações laboratoriais ao diagnóstico e o tratamento de crianças e adolescentes com doença de Wilson. MÉTODOS: Estudo descritivo e retrospectivo de 17 crianças e adolescentes com doença de Wilson atendidos no Ambulatório de Hepatologia Pediátrica do Hospital das Clínicas da Universidade Federal de Minas Gerais no período de 1985 a 2008. Os dados foram coletados dos prontuários e durante as consultas ambulatoriais. RESULTADOS: A idade ao diagnóstico variou de 2,8 a 15,1 anos, com média de 8,8±0,9 anos. A forma de apresentação predominante foi hepática (53 por cento), seguida por assintomáticos provenientes de triagem familiar. O anel de Kayser-Fleischer foi encontrado em 41 por cento dos pacientes. A ceruloplasmina encontrava-se alterada em 15/17 pacientes e o cobre urinário variou de 24 a 1000mcg/24h (mediana: 184mcg/24h). O tratamento instituído foi a D-penicilamina. Observaram-se efeitos colaterais em cinco crianças, sem necessidade de interrupção ou troca da medicação. As respostas clínica e laboratorial, com níveis normais de aminotransferases, foram evidenciadas em 14 pacientes após mediana de 10,7 meses de tratamento. Três crianças morreram (uma por hepatite fulminante e duas com complicações da insuficiência hepática grave), apesar do tratamento. CONCLUSÕES: A doença de Wilson é rara na faixa etária pediátrica. A forma de apresentação predominante é a hepática. Seu diagnóstico se baseia principalmente em dosagem de ceruloplasmina baixa, cobre livre e cobre em urina de 24 horas elevados, mas exige alto grau de suspeição. Apresenta boa resposta e tolerância ao tratamento medicamentoso.

OBJECTIVE: To describe clinical symptoms, laboratory findings at diagnosis and treatment of children and adolescents with Wilson's disease. METHODS: This is a descriptive and retrospective study of a series of 17 children and adolescents with Wilson's disease, assited at the Pediatric Hepatology Ambulatory of the Hospital das Clínicas of Universidade Federal de Minas Gerais, Brazil, from 1985 to 2008. Data were collected by revision of medical charts and during clinical follow-up. RESULTS: Patients were 2.8 to 15.1 years old, with a mean age of 8.8±0.9 years. The disease main presentation was hepatic (53 percent), followed by the asymptomatic form, diagnosed by family screening. The Kayser-Fleischer ring was observed in 41 percent of the patients. The ceruloplasmin was altered in 15 out of 17 patients, and the urinary copper varied from 24 to 1000mcg/24h (median: 184mcg/24h). The treatment was stablished with D-penicillamine in all cases. Slight side effects were observed in five children, with no need to interrupt or change medication. Clinical and laboratory responses to treatment, with normalization of aminotransferases levels, were shown in 14 patients after a median of 10.7 months. Although treated, three patients died (one due to fulminant hepatitis and two due to severe hepatic failure). CONCLUSIONS: Wilson's disease is rare in the pediatric group. In children, the main presentation is the liver disease. The diagnosis can be established by reduced ceruloplasmin levels and elevated copper excretion in the 24-hour urine, but it demands high suspicion level. There are good tolerance and response to medical treatment.

Assuntos